EYPT vs. TXG, TRNS, CTKB, LAB, SENS, ALNT, AEHR, QSI, QTRX, and FEIM
Should you be buying EyePoint Pharmaceuticals stock or one of its competitors? The main competitors of EyePoint Pharmaceuticals include 10x Genomics (TXG), Transcat (TRNS), Cytek Biosciences (CTKB), Standard BioTools (LAB), Senseonics (SENS), Allient (ALNT), Aehr Test Systems (AEHR), Quantum-Si (QSI), Quanterix (QTRX), and Frequency Electronics (FEIM). These companies are all part of the "measuring and control equipment" industry.
EyePoint Pharmaceuticals vs.
10x Genomics (NASDAQ:TXG) and EyePoint Pharmaceuticals (NASDAQ:EYPT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, risk, valuation, earnings, dividends, institutional ownership, profitability, community ranking and analyst recommendations.
10x Genomics presently has a consensus target price of $19.79, suggesting a potential upside of 142.47%. EyePoint Pharmaceuticals has a consensus target price of $26.63, suggesting a potential upside of 369.58%. Given EyePoint Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe EyePoint Pharmaceuticals is more favorable than 10x Genomics.
EyePoint Pharmaceuticals has lower revenue, but higher earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than EyePoint Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
EyePoint Pharmaceuticals received 406 more outperform votes than 10x Genomics when rated by MarketBeat users. Likewise, 70.27% of users gave EyePoint Pharmaceuticals an outperform vote while only 51.24% of users gave 10x Genomics an outperform vote.
In the previous week, 10x Genomics had 17 more articles in the media than EyePoint Pharmaceuticals. MarketBeat recorded 19 mentions for 10x Genomics and 2 mentions for EyePoint Pharmaceuticals. EyePoint Pharmaceuticals' average media sentiment score of 1.72 beat 10x Genomics' score of 0.64 indicating that EyePoint Pharmaceuticals is being referred to more favorably in the news media.
84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 99.4% of EyePoint Pharmaceuticals shares are held by institutional investors. 10.0% of 10x Genomics shares are held by insiders. Comparatively, 4.7% of EyePoint Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
10x Genomics has a net margin of -29.90% compared to EyePoint Pharmaceuticals' net margin of -226.57%. 10x Genomics' return on equity of -25.40% beat EyePoint Pharmaceuticals' return on equity.
10x Genomics has a beta of 2.01, meaning that its stock price is 101% more volatile than the S&P 500. Comparatively, EyePoint Pharmaceuticals has a beta of 1.39, meaning that its stock price is 39% more volatile than the S&P 500.
Summary
EyePoint Pharmaceuticals beats 10x Genomics on 10 of the 18 factors compared between the two stocks.
Get EyePoint Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for EYPT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
EyePoint Pharmaceuticals Competitors List
Related Companies and Tools
This page (NASDAQ:EYPT) was last updated on 4/16/2025 by MarketBeat.com Staff
Buy EYPT Stock Free EYPT Stock Alerts